GPR18 is a G protein-coupled receptor (GPCR) that is expressed in lymphoid tissues, lung, brain, testis, and ovaries.1 It is coupled to the Gai/o and Gaq/11 transduction pathways and is activated by the polyunsaturated fatty acid metabolite resolvin D2 (Item No. 10007279) and the endocannabinoid arachidonoyl glycine (NAGly; Item No. 90051) in a context-dependent manner.1,2 Resolvin D2-induced activation of GPR18 reduces inflammatory pain induced by formalin, carrageenan, and complete Freund's adjuvant (CFA) in rats and reduces production of pro-inflammatory cytokines in mouse models of cecal ligation and puncture-induced sepsis, ocular infections, and ischemic injury.3,4 NAGly-induced activation of GPR18 lowers intraocular pressure (IOP) in mice in a fatty acid amide hydrolase-dependent manner.5 GPR18 is also overexpressed and constitutively active in patient-derived metastatic melanoma tumor samples.6 Cayman's GPR18 (C-Term) Polyclonal Antibody can be used for ELISA and immunohistochemistry (IHC) applications. The antibody recognizes the C-terminal region of GPR18 from human samples.WARNING This product is not for human or veterinary use.
